Lemaitre Vascular (LMAT) Tops Q1 EPS by 1c

Lemaitre Vascular (NASDAQ: LMAT) reported Q1 EPS of $0.16, $0.01 better than the analyst estimate of $0.15. Revenue for the quarter came in at $24.1 million versus the consensus estimate of $23.49 million.

GUIDANCE:

Lemaitre Vascular sees Q2 2017 EPS of $0.17, versus the consensus of $0.17. Lemaitre Vascular sees Q2 2017 revenue of $25.4 million, versus the consensus of $25 million.

Sees FY 2017 EPS of $0.70, versus the consensus of $0.66. Sees FY 2017 revenues of $100 million, versus the consensus of $99.0 million.

For earnings history and earnings-related data on Lemaitre Vascular (LMAT) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance